

Eximius Control BASIC

Triple set Coagulation controls



| | | | | | | |
|------------|--|-------------|------------|--|------------|--|
| REF | MRX170 Triple pack 4+4+2 x 1mL MRX171 Level 1 10x1 mL MRX172 Level 2 10x1 mL MRX173 Level 3 10x1 mL | EXP 2014-06 | LOT | Triple pack 13197 Level 1 13194 Level 2 13195 Level 3 13196 | IVD | For In Vitro Diagnostic Use In-vitro Diagnostikum in vitro diagnostisk produkt De uso diagnóstico in vitro In vitro diagnostiskt produkter |
|------------|--|-------------|------------|--|------------|--|

| ASSAY AND REAGENT TYPE | | Art. MRX171 LOT 13194 | | Art. MRX172 LOT 13195 | | Art. MRX173 LOT 13196 | |
|--|-------------------------|--------------------------|-------------|--------------------------|-----------|--------------------------|--------|
| Product No/Product Name | | Level 1 | | Level 2 | | Level 3 | |
| Prothrombin Time (PT) | | Mean | ± 2SD | Mean | ± 2SD | Mean | ± 2SD |
| MediRox GHI131-10 Owren PT | INR | 1,05 | N.A. | 2,54 | N.A. | 3,56 | N.A. |
| 20301800 HemosIL PT RecombiPlasTin 2G | INR | 0,94 | 0,84-1,04 | 2,28 | 1,96-2,60 | 3,36 | N.A. |
| HemosIL PT Recombiplastin | INR | 0,96 | 0,85-1,07 | 2,31 | 1,96-2,66 | N.A. | N.A. |
| HemosIL PT-Fib HS Plus | INR | 0,98 | 0,88-1,08 | 2,51 | 2,05-2,97 | N.A. | N.A. |
| Roche STA Neoplastin plus | INR | 0,95 | 0,85-1,05 | 2,70 | 2,29-3,11 | N.A. | N.A. |
| Sclavo PT | INR | 1,04 | 0,95-1,13 | 2,85 | 2,21-3,49 | N.A. | N.A. |
| Siemens PT Innovin | INR | 1,05 | 0,96-1,14 | 2,25 | 2,00-2,50 | N.A. | N.A. |
| Siemens Thromborel S | INR | 0,98 | 0,87-1,09 | 2,36 | 1,86-2,86 | N.A. | N.A. |
| MediRox GHI131-10 Owren PT | Seconds | 26 | N.A. | 65 | N.A. | 93 | N.A. |
| 20301800 HemosIL PT RecombiPlasTin 2G | Seconds | 11 | N.A. | 27 | N.A. | 39 | N.A. |
| Thrombin Time (TT) | | Mean | ± 2SD | Mean | ± 2SD | Mean | ± 2SD |
| 9758515 HemosIL Thrombin Time | Seconds | 16,6 | N.A. | N.A. | N.A. | N.A. | N.A. |
| Activated Partial Thromboplastin time (APTT) | | Mean | ± 2SD | Mean | ± 2SD | Mean | ± 2SD |
| MediRox MRX930, MRX931 APTT | Seconds | 30 | N.A. | 64 | N.A. | 83 | N.A. |
| 20006300 HemosIL APTT-SP | Seconds | 28 | 25-31 | 57 | 47-66 | 77 | 63-91 |
| HemosIL SynthASi APTT | Seconds | 31 | 27-36 | 51 | 39-63 | N.A. | N.A. |
| Siemens APTT Pathrombin SL | Seconds | 37 | 35-39 | 86 | 73-98 | 133 | 99-168 |
| Siemens Actin FS | Seconds | 33 | 26-39 | 62 | 48-76 | N.A. | N.A. |
| Sclavo APTT | Seconds | 32 | 31-33 | 66 | 60-72 | N.A. | N.A. |
| Roche STA Cephascreen APTT | Seconds | 33 | 31-34 | 58 | 56-60 | N.A. | N.A. |
| Fibrinogen | | Mean | ± 2SD | Mean | ± 2SD | Mean | ± 2SD |
| 20301800 HemosIL QFA Thrombin | mg/dL | 272 | 242-303 | 157 | 127-187 | 103 | N.A. |
| HemosIL Fib-C | mg/dL | 264 | 189-340 | 152 | 80-223 | N.A. | N.A. |
| Siemens Thrombin | mg/dL | 259 | 226-292 | 159 | 142-176 | N.A. | N.A. |
| Siemens Multifibren U | mg/dL | 280 | 211-348 | 204 | 142-256 | N.A. | N.A. |
| Sclavo Fibrinogen | mg/dL | 275 | 227-323 | 184 | 153-215 | N.A. | N.A. |
| ROCHE STA Fibrinogen | mg/dL | 284 | 257-310 | 175 | 162-187 | N.A. | N.A. |
| Antithrombin III (ATIII) | | Mean | ± 2SD | Mean | ± 2SD | Mean | ± 2SD |
| MediRox MRX1200 Antithrombin Liquid | IU/mL | 0,98 | N.A. | 0,45 | N.A. | 0,28 | N.A. |
| 2030100 HemosIL Liquid Antithrombin | % | 101 | 93-108 | 39 | 31-48 | 23 | N.A. |
| IL Antithrombin III Chromogenic | % | 101 | 92-111 | 40 | 31-48 | N.A. | N.A. |
| Siemens Innovance Antithrombin | % | 103 | 85-121 | 42 | 28-56 | N.A. | N.A. |
| Siemens Berichrom Antithrombin III | % | 100 | 95-106 | 40 | 31-49 | N.A. | N.A. |
| Sclavo Antithrombin | % | 98 | 82-113 | 39 | 21-58 | N.A. | N.A. |
| D-dimer | | Mean | ± 2SD | Mean | ± 2SD | Mean | ± 2SD |
| MediRox MRX143 D-dimer | mg/L DDU | 0,36 | N.A. | 0,96 | N.A. | 2,47 | N.A. |
| MediRox MRX143 D-dimer | mg/L FEU ^{1/2} | 0,72 | N.A. | 1,92 | N.A. | 4,94 | N.A. |
| 20007700 HemosIL D-Dimer HS | ng/mL (DDU) | 355 | N.A. | 899 | N.A. | 2473 | N.A. |
| 20008500 HemosIL D-Dimer | ng/mL (DDU) | 386 | 256-515 | 809 | 698-919 | 1906 | N.A. |
| Siemens Innovance D-Dimer | ng/mL (FEU) | 1175 | 1071-1278 | 3144 | 2779-3509 | N.A. | N.A. |
| Roche STA D-Dimer LIA | µg/mL (FEU) | 0,644 | 0,468-0,820 | 1,62 | 1,48-1,76 | N.A. | N.A. |

NOTE

Note that the results for each independent laboratory may differ considerably depending on laboratory techniques, instrument settings and reagent depending factors. Therefore each laboratory should establish its own means and reference ranges and use those provided only as a guideline.

Mean values and ± 2SD have been established by the usage of several instruments with separate calibration systems. Sample to sample variation should be significantly smaller than the given range. Refer to reagent insert for expected sample to sample variation.

N.A.: Parameters are established using single instrument analysis, hence no ± 2SD values are provided.

[1] MRX143 D-dimer levels are reported both as mg/L DDU and mg/L FEU. For a conversion to FEU a factor of 2 is generally used even if a stoichiometrical calibration would suggest a different factor. References: Fedde van der Graaf, Henk van der Horst, Marion van der Kolk, Pietje de Wild, Ger W.T Janssen, Stan H.M. van Uum. Exclusion of Deep Venous Thrombosis with D-Dimer Testing. Bror Edlund, Torbjörn K. Nilsson. A proposed stoichiometrical calibration procedure to achieve transferability of D-Dimer measurements and to Characterize the performance of different methods.